S1013 |
Bortezomib
|
Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors. |
-
Cell, 2024, 187(18):4905-4925.e24
-
Cell, 2024, S0092-8674(24)00315-5
-
Cell, 2024, S0092-8674(24)00653-6
|
|
S7101 |
SCH772984
|
SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells. |
-
Nature, 2024, 629(8013):927-936
-
Nat Commun, 2024, 15(1):383
-
Nat Commun, 2024, 15(1):8002
|
|
S1014 |
Bosutinib
|
Bosutinib is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy. |
-
Elife, 2024, 12RP92324
-
Front Immunol, 2024, 15:1425670
-
PLoS Pathog, 2024, 20(7):e1012170
|
|
S1531 |
BIX 02189
|
BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with IC50 of 59 nM in cell-free assays, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2. |
-
PLoS One, 2024, 19(1):e0295629
-
Nat Commun, 2023, 10.1038/s41467-023-43369-x
-
Exp Mol Med, 2023, 55(6):1247-1257
|
|
S1396 |
Resveratrol
|
Resveratrol has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases(LOX, IC50=2.7 μM), kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects. Resveratrol induces mitophagy/autophagy and autophagy-dependent apoptosis. |
-
Biochem Biophys Res Commun, 2024, 723:150186
-
J Hazard Mater, 2023, 10.1016/j.jhazmat.2023.132932
-
Cell Death Dis, 2023, 14(6):367
|
|
S7554 |
Ravoxertinib (GDC-0994)
|
Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1. |
-
Nature, 2024, 629(8013):927-936
-
Nat Commun, 2024, 15(1):7037
-
Cell Rep Med, 2024, S2666-3791(24)00372-0
|
|
S7854 |
Ulixertinib (BVD-523)
|
Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1. |
-
Nature, 2024, 629(8013):927-936
-
Acta Pharm Sin B, 2024, 14(3):1187-1203
-
J Adv Res, 2024, 60:141-157
|
|
S8534 |
Temuterkib (LY3214996)
|
Temuterkib (LY3214996) is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines.
|
-
Nat Commun, 2024, 15(1):2581
-
Nat Commun, 2024, 15(1):7037
-
Nat Commun, 2024, 15(1):1300
|
|
S7524 |
FR 180204
|
FR 180204 is an ATP-competitive, selective ERK inhibitor with Ki of 0.31 μM and 0.14 μM for ERK1 And ERK2, respectively. It is 30-fold less potent against the related kinase p38α and failed to inhibit any kinases(MEK1, MKK4, IKKα, PKCα, Src, Syc, and PDGFα) at less than 30 μM. |
-
Neural Regen Res, 2024, 19(1):180-189
-
Cancers (Basel), 2024, 16(13)2447
-
Int J Mol Sci, 2023, 24(7)6228
|
|
S7525 |
XMD8-92
|
XMD8-92 is a potent and selective dual inhibitor of big map kinase (BMK1, ERK5) and bromodomain-containing proteins (BRDs, BET) with Kd of 80 nM and 170 nM for ERK5 and BRD4(1), respectively. |
-
Stem Cell Reports, 2024, S2213-6711(24)00216-9
-
Mol Biol Rep, 2024, 51(1):313
-
Nat Commun, 2023, 10.1038/s41467-023-43369-x
|
|
S7709 |
VX-11e
|
VX-11e (VTX-11e, Vertex-11e) is a potent, selective, and orally bioavailable ERK inhibitor with IC50 of 17 nM (ERK1) and 15 nM (ERK2), over 200-fold selective over other kinases tested.
|
-
Nat Commun, 2024, 15(1):2581
-
Nat Commun, 2024, 15(1):7037
-
Int J Biol Sci, 2024, 20(2):569-584
|
|
S8708 |
AZD0364 (ATG-017)
|
AZD0364 (ATG-017) is a pre-clinical ERK1/2 inhibitor with an IC50 of 0.6 nM for ERK2. |
-
Nature, 2024, 629(8013):927-936
-
Elife, 2024, 12RP91507
-
J Clin Biochem Nutr, 2024, 74(2):97-107
|
|
S7334 |
ERK5-IN-1
|
ERK5-IN-1 (XMD17-109) is a potent, and selective ERK5 inhibitor with IC50 of 162 nM.
|
-
JCI Insight, 2024, 9(10)e164191
-
Nat Commun, 2023, 14(1):3364
-
J Med Chem, 2021, 10.1021/acs.jmedchem.1c01096
|
|
S8701 |
MK-8353 (SCH900353)
|
MK-8353 (SCH900353) is an orally bioavailable, selective, and potent ERK inhibitor that inhibits activated ERK1 and ERK2 in vitro, with IC50 values of 23.0 nM and 8.8 nM, respectively (IMAP kinase assay), and nonactivated ERK2, with an IC50 of 0.5 nM (MEK1-ERK2-coupled assay). |
-
J Exp Clin Cancer Res, 2023, 42(1):75
-
J Exp Clin Cancer Res, 2023, 42(1):75
-
Life Sci Alliance, 2023, 6(8)e202201685
|
|
S7921 |
DEL-22379
|
DEL-22379 is a water-soluble ERK dimerization inhibitor with IC50 of ∼0.5 μM.
|
-
Cells, 2022, 11(3)425
-
Cells, 2022, 11(3)425
-
Front Mol Biosci, 2022, 9:1030725
|
|
S3901 |
Astragaloside IV
|
Astragaloside IV (AST-IV, AS-IV) is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine. It has various effect on the cardiovascular, immune, digestive, and nervous systems. AS-IV suppresses activation of p-Akt, p-mTOR, p-NF-κB and p-Erk1/2. |
-
Cell Transplant, 2023, 32:9636897231198167
-
Cell Transplant, 2023, 32:9636897231198167
-
Cell Cycle, 2022, 1-14
|
|
S8569 |
KO-947
|
KO-947 is a potent and selective inhibitor of ERK1/2 kinases. KO-947 blocks ERK signaling and proliferation of tumor cells exhibiting dysregulation of MAPK pathway signaling at low nanomolar concentrations. |
-
Phytomedicine, 2022, 98:153963
-
CNS Neurosci Ther, 2022, 10.1111/cns.13945
-
Front Endocrinol (Lausanne), 2022, 13:896753
|
|
S9102 |
Magnolin
|
Magnolin is a natural compound abundantly found in Magnolia flos targeting ERK1 (IC50=87 nM) and ERK2 (IC50=16.5 nM) and inhibits cell transformation induced by tumor promoters such as epidermal growth factor (EGF). |
-
Cell Rep, 2023, 42(4):112294
-
Cell Adhesion & Migration, 2023, 17(1)
-
Connect Tissue Res, 2020, 1-10
|
|
S0881 |
Mitochonic acid 5 (MA-5)
|
Mitochonic acid 5 (MA-5) reduces mitochondrial apoptosis via upregulation of mitophagy. Mitochonic acid 5 regulates mitophagy via Bnip3 through the MAPK-ERK-Yap signaling pathway. Mitochonic acid 5 modulates mitochondrial ATP synthesis. |
-
Animals (Basel), 2024, 14(3):368.
-
Animals (Basel), 2024, 14(3)368
-
J Ovarian Res, 2022, 15(1):103
|
|
S3275 |
Senkyunolide I
|
Senkyunolide I (SEI, SENI) is an orally active compound isolated from Ligusticum chuanxiong with analgesic, anti-migraine, neuroprotective, anti-oxidation and anti-apoptosis activities. Senkyunolide I (SEI, SENI) up-regulates the phosphorylation of Erk1/2 and induces Nrf2 nuclear translocation with enhanced HO-1 and NQO1 expressions. Senkyunolide I (SEI, SENI) promotes the ratio of Bcl-2/Bax and inhibits the expressions of cleaved caspase 3 and caspase 9. |
-
iScience, 2024, 27(7):110367
-
World J Emerg Med, 2024, 15(3):206-213
-
SSRN , 2024, 10.2139/ssrn.4696834
|
|
S3292 |
Falcarindiol
|
Falcarindiol (FAD, (3R,8S)-Falcarindiol, FaDOH) is a natural polyacetylene compound found rich in many plants of the Umbelliferae family. Falcarindiol suppresses LPS-stimulated expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Falcarindiol attenuates the LPS-induced activation of JNK, ERK, STAT1, and STAT3 signaling molecules. |
-
Front Cell Infect Microbiol, 2023, 13:1128000
-
Front Pharmacol, 2021, 12:656697
|
|
S7752 |
Pluripotin (SC1)
|
Pluripotin (SC1) is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP. Maintains embryonic stem cell (ESC) self-renewal. Pluripotin also inhibits RSK1, RSK2, RSK3 and RSK4 with IC50 of 0.5 µM, 2.5 µM, 3.3 µM and 10.0 µM, respectively. |
-
J Clin Biochem Nutr, 2024, 74(2):97-107
-
Antiviral Res, 2018, 157:57-67
-
Reprod Domest Anim, 2018, 53(5):1052-1059
|
|
E2203 |
DMU-212
|
DMU-212 is a methylated derivative of Resveratrol, with antimitotic, anti-proliferative, antioxidant and apoptosis promoting activities, which can induce mitotic arrest via induction of apoptosis and activation of extracellular-signal-regulated kinase1/2 (ERK1/2) protein. |
-
Blood Sci, 2023, 5(3):160-169
|
|
S3785 |
Notoginsenoside R1
|
Notoginsenoside R1 (Sanchinoside R1) is the main ingredient with cardiovascular activity in Panax notoginseng. It inhibits TNF-α-induced PAI-1 overexpression via extracellular signal-related kinases (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathways. |
-
Food Sci Nutr, 2023, 11(12):7791-7802
-
J Ethnopharmacol, 2021, S0378-8741(21)00169-0
|
|
S8801 |
CC-90003
|
CC-90003 is an irreversible inhibitor of ERK1/2 with IC50s in the 10-20 nM range and shows good kinase selectivity in a 258-kinase biochemical assay. |
-
Cancer Res Commun, 2024, 10.1158/2767-9764.CRC-24-0221
-
Cell Death Discov, 2021, 7(1):375
|
|
S8896 |
BAY-885
|
BAY-885 is a highly potent and selective ERK5 inhibitor. |
-
Bioengineered, 2022, 13(5):12888-12898
|
|
S9374 |
2',5'-Dihydroxyacetophenone
|
2',5'-Dihydroxyacetophenone (DHAP, 2-Acetylhydroquinone, Quinacetophenone) is a mixture of dihydroxyacetophenone isomers is used in food flavouring. 2',5'-Dihydroxyacetophenone significantly inhibits NO production via the suppression of iNOS expression. 2',5'-Dihydroxyacetophenone significantly decreases levels of the pro-inflammatory cytokines TNF-α and IL-6 by blocking the ERK1/2 and NF-κB signaling pathways. |
-
Pathol Oncol Res, 2019, 25(1):301-309
|
|
S0454 |
Adjudin
|
Adjudin (AF-2364), a potent male contraceptive, is a potent blocker of Cl⁻ channels. Adjudin exhibits anti-inflammatory properties by suppression of NF-κB p65 nuclear translocation and DNA binding activity as well as ERK MAPK phosphorylation. |
-
Brain Res Bull, 2022, 182:80-89
|
|
S6596 |
AG-126
|
AG126 is a tyrosine kinase inhibitor which selectively inhibits the phosphorylation of ERK1 (p44) and ERK2 (p42) at 25-50 μM. |
-
J Immunol, 2019, 203(12):3225-3236
|
|
S3940 |
3'-Hydroxypterostilbene
|
3'-Hydroxypterostilbene (3'-HPT) is one of the active constituents of Sphaerophysa salsula and Pterocarpus marsupium which may be useful in treating different types of haematological malignancies. 3'-Hydroxypterostilbene, a natural pterostilbene analogue, effectively inhibits the growth of human colon cancer cells (IC50s of 9.0, 40.2, and 70.9 µM for COLO 205, HCT-116, and HT-29 cells, respectively) by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene inhibits the PI3K/Akt/mTOR/p70S6K, and p38MAPK pathways and activates the ERK1/2, JNK1/2 MAPK pathways. |
-
Int J Mol Sci, 2024, 25(18)9990
|
|
S0911 |
Hypaphorine
|
Hypaphorine which is abundantly found in vaccaria semen, counteracts inflammation via inhibition of ERK or/and NFκB signaling pathways. |
|
|
S8961 |
Alobresib (GS-5829)
|
Alobresib (GS-5829) is a novel BET inhibitor that represents a highly effective therapeutics agent against recurrent/chemotherapy-resistant USC-overexpressing c-Myc. Alobresib (GS-5829) inhibits CLL cell proliferation and induces leukemia cell apoptosis through deregulation of key signaling pathways, such as BLK, AKT, ERK1/2, and MYC. Alobresib (GS-5829) also inhibits NF-κB signaling. |
|
|
S0726 |
XMD8-85 (ERK5-IN-1)
|
XMD8-85 (ERK5-IN-1) is a selective and potent inhibitor of ERK5 and LRRK2 with IC50s of 0.162 μM and 0.339 μM, respectively. |
|
|
S3242 |
Loureirin B
|
Loureirin B (LB, LrB), a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of PAI-1 with IC50 of 26.10 μM. Loureirin B downregulates p-ERK and p-JNK in TGF-β1-stimulated fibroblasts. Loureirin B promotes insulin secretion mainly through increasing Pdx-1, MafA, intracellular ATP level, inhibiting the KATP current, influx of Ca2+ to the intracellular. |
|
|
S9975 |
ASN007
|
ASN007(ERAS 007, ERK-IN-3) is a potent and orally active inhibitor of ERK. ERK-IN-3 inhibits ERK1/2 with 2 nM IC50 values. ERK-IN-3 can be used for the research of cancers driven by RAS mutations. |
|
|
S0949 |
Cucurbitacin IIb
|
Cucurbitacin IIb (CuIIb, Dihydrocucurbitacin F, 25-deacetyl hemslecin A) inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB, blocks nuclear translocation of NF-κB and decreases mRNA levels of IκBα and TNF-α. Cucurbitacin IIb exhibits anti-inflammatory activity and induces apoptosis. Cucurbitacin IIb is isolated from Hemsleya amabilis. |
|
|
S4884 |
Trans-Zeatin
|
Trans-Zeatina ((E)-Zeatin) is the member of the plant growth hormone family known as cytokinins, which regulate cell division, development, and nutrient processing. Trans-Zeatin inhibits UVB-induced MMP-1 expression, c-Jun activation and phosphorylation of ERK, JNK and p38 MAP kinases (MAPKs) dose-dependently. |
|
|
S4953 |
Usnic acid
|
Usnic acid (Usniacin) is a furandione found uniquely in lichen that is used widely in cosmetics, deodorants, toothpaste and medicinal creams as well as some herbal products. It exhibits antiviral, antiprotozoal, antiproliferative, anti-inflammatory and analgesic activity. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. |
|
|
S9698 |
Ezatiostat
|
Ezatiostat, a tripeptide analog of glutathione, is a peptidomimetic inhibitor of Glutathione S-transferase P1-1 (GSTP1-1). Ezatiostat activates c-Jun NH2 terminal kinase (JNK1) and ERK1/ERK2 and induces apoptosis. |
|
|
S0872 |
ASTX-029
|
ASTX-029 is an orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. ASTX-029 inhibits ERK-dependent tumor cell proliferation and survival. |
|
|
E3276 |
Red Ginseng Extract
|
Red Ginseng Extract is derived from Red Ginseng, which can increase the human body's anti-inflammatory and anticancer immunity. |
|
|
S6920 |
SEA0400
|
SEA0400 is a selective and potent inhibitor of the Na+-Ca2+ exchanger (NCX) that inhibits Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia with IC50 of 33 nM, 5.0 nM and 8.3 nM, respectively. SEA0400 prevents sodium nitroprusside (SNP) from increasing ERK and p38 MAPK phosphorylation and production of reactive oxygen species (ROS) in an extracellular Ca(2+)-dependent manner. |
|
|
S6760 |
LM22B-10
|
LM22B-10 is a small molecule TrkB/TrkC neurotrophin receptor co-activator, LM22B-10 selectively activates TrkB, TrkC, AKT and ERK in vivo and in vitro. |
-
Theranostics, 2024, 14(4):1561-1582
-
Int J Mol Sci, 2024, 25(4)2408
-
Sci Rep, 2024, 14(1):12090
|
|
S6882 |
HI-TOPK-032
|
HI-TOPK-032 is a potent and specific inhibitor of TOPK. HI-TOPK-032 also reduces ERK-RSK phosphorylation, regulates of the abundance of p53, cleaved caspase-7, and cleaved PARP, and induces apoptosis in cancer cells. |
|
|
E0102 |
I-191
|
I-191 is a potent PAR2 antagonist that inhibits multiple PAR2-induced signaling pathways and functional responses. I-191 also inhibits ERK1/2 phosphorylation, RhoA activation, and inhibition of forskolin-stimulated cAMP accumulation induced by micromolar concentrations of biased ligand GB88.
|
|
|
S0844 |
NDMC101
|
NDMC101 inhibits osteoclastogenesis which also ameliorates paw swelling and inflammatory bone destruction, associating with the inhibition of such transcription factors as NF-κB and NFATc1 as well as multiple protein kinases, including p38, ERK, and JNK. |
|
|
S9075 |
Mulberroside A
|
Mulberroside A, isolated from the ethanol extract of Morus alba roots, is widely employed as an active ingredient in cosmetic products due to its anti-tyrosinase and anti-oxidant activities. Mulberroside A decreases the expressions of TNF-α, IL-1β and IL-6 and inhibits the activation of NALP3, caspase-1 and NF-κB and the phosphorylation of ERK, JNK and p38. |
|
|
S9665 |
Motixafortide (BL-8040)
|
Motixafortide (BL-8040, BKT140, TF 14016, 4-fluorobenzoyl, 4F-benzoyl-TN14003, T140) is an antagonist of CXCR4 with IC50 of ~1 nM. BL-8040 induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. |
|
|
S6177 |
CP 43
|
Cp 43 (Compound 43, TAO Kinase inhibitor 1, TAOK inhibitor 43) is a ATP-competitive and selective TAO Kinase inhibitor with IC50s of 11 nM and 15 nM for TAOK1 and TAOK2, respectively. |
|
|
S3138 |
Methylthiouracil
|
Methylthiouracil (NSC-193526, NSC-9378,MTU) is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2. |
|
|
S8831 |
MRTX-1257
|
MRTX-1257 is a potent, selective, irreversible, covalent and orally active inhibitor of KRAS G12C with IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells. |
|
|
E2660 |
Pamoic acid disodium
|
Pamoic acid disodium, a potent GPR35 agonist with an EC50 value of 79 nM, induces GPR35a internalization and activates ERK1/2 with EC50 values of 22 nM and 65 nM, respectively, also potently recruits β-arrestin2 to GPR35 showing an antinociceptive effect. |
|
|
S9306 |
Corynoxeine
|
Corynoxeine, which could be isolated from Uncaria rhynchophylla, is a useful and prospective compound in the prevention and treatment for vascular diseases. It is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC proliferation. |
|
|
S1321 |
Urolithin B
|
Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα. Urolithin B suppresses the phosphorylation of JNK, ERK, and Akt, and enhances the phosphorylation of AMPK. Urolithin B is also a regulator of skeletal muscle mass. |
|
|
S6786 |
ERK5-IN-2
|
ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50 of 0.82 μM and 3 μM for ERK5 and ERK5 MEF2D, respectively. |
|
|
S3284 |
Tracheloside
|
Tracheloside is a lignan glycoside isolated from seeds of Carthamus tinctorius with anti-estrogenic effects. Tracheloside significantly decreases the activity of alkaline phosphatase (AP) (an estrogen-inducible marker enzyme) with IC50 of 0.31 μg/ml. Tracheloside promotes keratinocyte proliferation through ERK1/2 stimulation. |
|
|
S7101 |
SCH772984
|
SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells. |
- Nature, 2024, 629(8013):927-936
- Nat Commun, 2024, 15(1):383
- Nat Commun, 2024, 15(1):8002
|
|
S1014 |
Bosutinib
|
Bosutinib is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively. Bosutinib also effectively decreases the activity of PI3K/AKT/mTOR, MAPK/ERK and JAK/STAT3 signaling pathways by blocking the phosphorylation levels of p-ERK, p-S6, and p-STAT3. Bosutinib promotes autophagy. |
- Elife, 2024, 12RP92324
- Front Immunol, 2024, 15:1425670
- PLoS Pathog, 2024, 20(7):e1012170
|
|
S1531 |
BIX 02189
|
BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with IC50 of 59 nM in cell-free assays, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2. |
- PLoS One, 2024, 19(1):e0295629
- Nat Commun, 2023, 10.1038/s41467-023-43369-x
- Exp Mol Med, 2023, 55(6):1247-1257
|
|
S1396 |
Resveratrol
|
Resveratrol has a wide spectrum of targets including cyclooxygenases(i.e. COX, IC50=1.1 μM), lipooxygenases(LOX, IC50=2.7 μM), kinases, sirtuins and other proteins. It has anti-cancer, anti-inflammatory, blood-sugar-lowering and other beneficial cardiovascular effects. Resveratrol induces mitophagy/autophagy and autophagy-dependent apoptosis. |
- Biochem Biophys Res Commun, 2024, 723:150186
- J Hazard Mater, 2023, 10.1016/j.jhazmat.2023.132932
- Cell Death Dis, 2023, 14(6):367
|
|
S7554 |
Ravoxertinib (GDC-0994)
|
Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1. |
- Nature, 2024, 629(8013):927-936
- Nat Commun, 2024, 15(1):7037
- Cell Rep Med, 2024, S2666-3791(24)00372-0
|
|
S7854 |
Ulixertinib (BVD-523)
|
Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1. |
- Nature, 2024, 629(8013):927-936
- Acta Pharm Sin B, 2024, 14(3):1187-1203
- J Adv Res, 2024, 60:141-157
|
|
S8534 |
Temuterkib (LY3214996)
|
Temuterkib (LY3214996) is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines.
|
- Nat Commun, 2024, 15(1):2581
- Nat Commun, 2024, 15(1):7037
- Nat Commun, 2024, 15(1):1300
|
|
S7524 |
FR 180204
|
FR 180204 is an ATP-competitive, selective ERK inhibitor with Ki of 0.31 μM and 0.14 μM for ERK1 And ERK2, respectively. It is 30-fold less potent against the related kinase p38α and failed to inhibit any kinases(MEK1, MKK4, IKKα, PKCα, Src, Syc, and PDGFα) at less than 30 μM. |
- Neural Regen Res, 2024, 19(1):180-189
- Cancers (Basel), 2024, 16(13)2447
- Int J Mol Sci, 2023, 24(7)6228
|
|
S7525 |
XMD8-92
|
XMD8-92 is a potent and selective dual inhibitor of big map kinase (BMK1, ERK5) and bromodomain-containing proteins (BRDs, BET) with Kd of 80 nM and 170 nM for ERK5 and BRD4(1), respectively. |
- Stem Cell Reports, 2024, S2213-6711(24)00216-9
- Mol Biol Rep, 2024, 51(1):313
- Nat Commun, 2023, 10.1038/s41467-023-43369-x
|
|
S7709 |
VX-11e
|
VX-11e (VTX-11e, Vertex-11e) is a potent, selective, and orally bioavailable ERK inhibitor with IC50 of 17 nM (ERK1) and 15 nM (ERK2), over 200-fold selective over other kinases tested.
|
- Nat Commun, 2024, 15(1):2581
- Nat Commun, 2024, 15(1):7037
- Int J Biol Sci, 2024, 20(2):569-584
|
|
S8708 |
AZD0364 (ATG-017)
|
AZD0364 (ATG-017) is a pre-clinical ERK1/2 inhibitor with an IC50 of 0.6 nM for ERK2. |
- Nature, 2024, 629(8013):927-936
- Elife, 2024, 12RP91507
- J Clin Biochem Nutr, 2024, 74(2):97-107
|
|
S7334 |
ERK5-IN-1
|
ERK5-IN-1 (XMD17-109) is a potent, and selective ERK5 inhibitor with IC50 of 162 nM.
|
- JCI Insight, 2024, 9(10)e164191
- Nat Commun, 2023, 14(1):3364
- J Med Chem, 2021, 10.1021/acs.jmedchem.1c01096
|
|
S8701 |
MK-8353 (SCH900353)
|
MK-8353 (SCH900353) is an orally bioavailable, selective, and potent ERK inhibitor that inhibits activated ERK1 and ERK2 in vitro, with IC50 values of 23.0 nM and 8.8 nM, respectively (IMAP kinase assay), and nonactivated ERK2, with an IC50 of 0.5 nM (MEK1-ERK2-coupled assay). |
- J Exp Clin Cancer Res, 2023, 42(1):75
- J Exp Clin Cancer Res, 2023, 42(1):75
- Life Sci Alliance, 2023, 6(8)e202201685
|
|
S7921 |
DEL-22379
|
DEL-22379 is a water-soluble ERK dimerization inhibitor with IC50 of ∼0.5 μM.
|
- Cells, 2022, 11(3)425
- Cells, 2022, 11(3)425
- Front Mol Biosci, 2022, 9:1030725
|
|
S3901 |
Astragaloside IV
|
Astragaloside IV (AST-IV, AS-IV) is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine. It has various effect on the cardiovascular, immune, digestive, and nervous systems. AS-IV suppresses activation of p-Akt, p-mTOR, p-NF-κB and p-Erk1/2. |
- Cell Transplant, 2023, 32:9636897231198167
- Cell Transplant, 2023, 32:9636897231198167
- Cell Cycle, 2022, 1-14
|
|
S8569 |
KO-947
|
KO-947 is a potent and selective inhibitor of ERK1/2 kinases. KO-947 blocks ERK signaling and proliferation of tumor cells exhibiting dysregulation of MAPK pathway signaling at low nanomolar concentrations. |
- Phytomedicine, 2022, 98:153963
- CNS Neurosci Ther, 2022, 10.1111/cns.13945
- Front Endocrinol (Lausanne), 2022, 13:896753
|
|
S9102 |
Magnolin
|
Magnolin is a natural compound abundantly found in Magnolia flos targeting ERK1 (IC50=87 nM) and ERK2 (IC50=16.5 nM) and inhibits cell transformation induced by tumor promoters such as epidermal growth factor (EGF). |
- Cell Rep, 2023, 42(4):112294
- Cell Adhesion & Migration, 2023, 17(1)
- Connect Tissue Res, 2020, 1-10
|
|
S3292 |
Falcarindiol
|
Falcarindiol (FAD, (3R,8S)-Falcarindiol, FaDOH) is a natural polyacetylene compound found rich in many plants of the Umbelliferae family. Falcarindiol suppresses LPS-stimulated expression of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Falcarindiol attenuates the LPS-induced activation of JNK, ERK, STAT1, and STAT3 signaling molecules. |
- Front Cell Infect Microbiol, 2023, 13:1128000
- Front Pharmacol, 2021, 12:656697
|
|
S7752 |
Pluripotin (SC1)
|
Pluripotin (SC1) is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP. Maintains embryonic stem cell (ESC) self-renewal. Pluripotin also inhibits RSK1, RSK2, RSK3 and RSK4 with IC50 of 0.5 µM, 2.5 µM, 3.3 µM and 10.0 µM, respectively. |
- J Clin Biochem Nutr, 2024, 74(2):97-107
- Antiviral Res, 2018, 157:57-67
- Reprod Domest Anim, 2018, 53(5):1052-1059
|
|
S3785 |
Notoginsenoside R1
|
Notoginsenoside R1 (Sanchinoside R1) is the main ingredient with cardiovascular activity in Panax notoginseng. It inhibits TNF-α-induced PAI-1 overexpression via extracellular signal-related kinases (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling pathways. |
- Food Sci Nutr, 2023, 11(12):7791-7802
- J Ethnopharmacol, 2021, S0378-8741(21)00169-0
|
|
S8801 |
CC-90003
|
CC-90003 is an irreversible inhibitor of ERK1/2 with IC50s in the 10-20 nM range and shows good kinase selectivity in a 258-kinase biochemical assay. |
- Cancer Res Commun, 2024, 10.1158/2767-9764.CRC-24-0221
- Cell Death Discov, 2021, 7(1):375
|
|
S8896 |
BAY-885
|
BAY-885 is a highly potent and selective ERK5 inhibitor. |
- Bioengineered, 2022, 13(5):12888-12898
|
|
S9374 |
2',5'-Dihydroxyacetophenone
|
2',5'-Dihydroxyacetophenone (DHAP, 2-Acetylhydroquinone, Quinacetophenone) is a mixture of dihydroxyacetophenone isomers is used in food flavouring. 2',5'-Dihydroxyacetophenone significantly inhibits NO production via the suppression of iNOS expression. 2',5'-Dihydroxyacetophenone significantly decreases levels of the pro-inflammatory cytokines TNF-α and IL-6 by blocking the ERK1/2 and NF-κB signaling pathways. |
- Pathol Oncol Res, 2019, 25(1):301-309
|
|
S0454 |
Adjudin
|
Adjudin (AF-2364), a potent male contraceptive, is a potent blocker of Cl⁻ channels. Adjudin exhibits anti-inflammatory properties by suppression of NF-κB p65 nuclear translocation and DNA binding activity as well as ERK MAPK phosphorylation. |
- Brain Res Bull, 2022, 182:80-89
|
|
S6596 |
AG-126
|
AG126 is a tyrosine kinase inhibitor which selectively inhibits the phosphorylation of ERK1 (p44) and ERK2 (p42) at 25-50 μM. |
- J Immunol, 2019, 203(12):3225-3236
|
|
S0911 |
Hypaphorine
|
Hypaphorine which is abundantly found in vaccaria semen, counteracts inflammation via inhibition of ERK or/and NFκB signaling pathways. |
|
|
S0726 |
XMD8-85 (ERK5-IN-1)
|
XMD8-85 (ERK5-IN-1) is a selective and potent inhibitor of ERK5 and LRRK2 with IC50s of 0.162 μM and 0.339 μM, respectively. |
|
|
S3242 |
Loureirin B
|
Loureirin B (LB, LrB), a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of PAI-1 with IC50 of 26.10 μM. Loureirin B downregulates p-ERK and p-JNK in TGF-β1-stimulated fibroblasts. Loureirin B promotes insulin secretion mainly through increasing Pdx-1, MafA, intracellular ATP level, inhibiting the KATP current, influx of Ca2+ to the intracellular. |
|
|
S9975 |
ASN007
|
ASN007(ERAS 007, ERK-IN-3) is a potent and orally active inhibitor of ERK. ERK-IN-3 inhibits ERK1/2 with 2 nM IC50 values. ERK-IN-3 can be used for the research of cancers driven by RAS mutations. |
|
|
S0949 |
Cucurbitacin IIb
|
Cucurbitacin IIb (CuIIb, Dihydrocucurbitacin F, 25-deacetyl hemslecin A) inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB, blocks nuclear translocation of NF-κB and decreases mRNA levels of IκBα and TNF-α. Cucurbitacin IIb exhibits anti-inflammatory activity and induces apoptosis. Cucurbitacin IIb is isolated from Hemsleya amabilis. |
|
|
S4884 |
Trans-Zeatin
|
Trans-Zeatina ((E)-Zeatin) is the member of the plant growth hormone family known as cytokinins, which regulate cell division, development, and nutrient processing. Trans-Zeatin inhibits UVB-induced MMP-1 expression, c-Jun activation and phosphorylation of ERK, JNK and p38 MAP kinases (MAPKs) dose-dependently. |
|
|
S4953 |
Usnic acid
|
Usnic acid (Usniacin) is a furandione found uniquely in lichen that is used widely in cosmetics, deodorants, toothpaste and medicinal creams as well as some herbal products. It exhibits antiviral, antiprotozoal, antiproliferative, anti-inflammatory and analgesic activity. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. |
|
|
S0872 |
ASTX-029
|
ASTX-029 is an orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. ASTX-029 inhibits ERK-dependent tumor cell proliferation and survival. |
|
|
S6920 |
SEA0400
|
SEA0400 is a selective and potent inhibitor of the Na+-Ca2+ exchanger (NCX) that inhibits Na+-dependent Ca2+ uptake in cultured neurons, astrocytes, and microglia with IC50 of 33 nM, 5.0 nM and 8.3 nM, respectively. SEA0400 prevents sodium nitroprusside (SNP) from increasing ERK and p38 MAPK phosphorylation and production of reactive oxygen species (ROS) in an extracellular Ca(2+)-dependent manner. |
|
|
S6882 |
HI-TOPK-032
|
HI-TOPK-032 is a potent and specific inhibitor of TOPK. HI-TOPK-032 also reduces ERK-RSK phosphorylation, regulates of the abundance of p53, cleaved caspase-7, and cleaved PARP, and induces apoptosis in cancer cells. |
|
|
E0102 |
I-191
|
I-191 is a potent PAR2 antagonist that inhibits multiple PAR2-induced signaling pathways and functional responses. I-191 also inhibits ERK1/2 phosphorylation, RhoA activation, and inhibition of forskolin-stimulated cAMP accumulation induced by micromolar concentrations of biased ligand GB88.
|
|
|
S9075 |
Mulberroside A
|
Mulberroside A, isolated from the ethanol extract of Morus alba roots, is widely employed as an active ingredient in cosmetic products due to its anti-tyrosinase and anti-oxidant activities. Mulberroside A decreases the expressions of TNF-α, IL-1β and IL-6 and inhibits the activation of NALP3, caspase-1 and NF-κB and the phosphorylation of ERK, JNK and p38. |
|
|
S9665 |
Motixafortide (BL-8040)
|
Motixafortide (BL-8040, BKT140, TF 14016, 4-fluorobenzoyl, 4F-benzoyl-TN14003, T140) is an antagonist of CXCR4 with IC50 of ~1 nM. BL-8040 induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. |
|
|
S6177 |
CP 43
|
Cp 43 (Compound 43, TAO Kinase inhibitor 1, TAOK inhibitor 43) is a ATP-competitive and selective TAO Kinase inhibitor with IC50s of 11 nM and 15 nM for TAOK1 and TAOK2, respectively. |
|
|
S3138 |
Methylthiouracil
|
Methylthiouracil (NSC-193526, NSC-9378,MTU) is an antithyroid agent. Methylthiouracil suppresses the production TNF-α and IL-6, and the activation of NF-κB and ERK1/2. |
|
|
S8831 |
MRTX-1257
|
MRTX-1257 is a potent, selective, irreversible, covalent and orally active inhibitor of KRAS G12C with IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells. |
|
|
S9306 |
Corynoxeine
|
Corynoxeine, which could be isolated from Uncaria rhynchophylla, is a useful and prospective compound in the prevention and treatment for vascular diseases. It is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC proliferation. |
|
|
S1321 |
Urolithin B
|
Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα. Urolithin B suppresses the phosphorylation of JNK, ERK, and Akt, and enhances the phosphorylation of AMPK. Urolithin B is also a regulator of skeletal muscle mass. |
|
|
S6786 |
ERK5-IN-2
|
ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50 of 0.82 μM and 3 μM for ERK5 and ERK5 MEF2D, respectively. |
|
|